Analysis of T cell subsets present in the peripheral blood and synovial fluid of reactive arthritis patients

Helen Beacock-Sharp, Joyce L Young, J S Hill Gaston

Abstract

Objective—Reactive arthritis (ReA), a HLA-B27 associated arthropathy, develops in susceptible people after infection with certain bacteria. T cells have been implicated in the pathogenesis of the arthritis but which of the different subsets is involved is still debated. This study has further elucidated the role of the CD4+ and CD8+ T cells by examining the expression of various surface markers associated with activation.

Methods—Three colour flow cytometry was used to examine the phenotype of the T cells within the synovial fluid (SF) and peripheral blood (PB) of ReA patients.

Results—ReA SF, compared with paired PB, contained a higher percentage of CD69+, CD25+, and HLA-DR+ CD3+ T cells. The majority of SF T cells also expressed the putative memory marker CD45RO. Within the T cell subsets, CD25 was expressed primarily on the CD4+ T cells; however more CD8+ T cells were HLA-DR+.

Conclusion—The results show that both CD4+ and CD8+ T cell populations demonstrate evidence of recent activation. Whether these cells are involved in inducing inflammation, regulating the inflammation, or have become active as a result of migration through the endothelium, remains to be determined by functional studies.


Reactive arthritis (ReA) develops in susceptible people after infection with various facultative (for example, yersinia and salmonella) or obligate (chlamydia) intracellular pathogens. The precise mechanisms underlying the disease are unknown but T cells are proposed to be involved. Immunohistochemistry has identified lymphocytes and neutrophils as the predominant cell types infiltrating the inflamed joint, and further analysis of the mononuclear cell (MC) populations isolated from the synovial fluid (SF) show that the majority of these are T lymphocytes, with some monocytes but very few B cells. There is also a strong association of the disease with the MHC class I molecule, HLA-B27, which presents intracellular antigens to CD8+ T cells. Additional evidence in favour of a role for T cells in the pathogenesis of ReA comes from the ability of SF derived T cells to proliferate in response to the organism that triggered the disease. T cells have also been implicated in causing the disease seen in an animal model of the HLA-B27 associated diseases that have been developed in Lewis rats. Rats that are transgenic for both HLA-B27 and human β2-microglobulin (hβ2M), and express these at the cell surface, spontaneously develop inflammatory disorders resembling the human spondyloarthropathy. T cells have been identified as having a pathogenic role in this animal model, as disease can be adoptively transferred to T cell deficient HLA-B27- nude rats, which do not otherwise develop symptoms, by T lymphocytes from transgenic rats.

The role of the CD4+ and CD8+ T cell subsets in the pathogenesis of ReA is still debated. As HLA-B27 presents antigens to CD8+ T cells, a simple hypothesis proposes that arthritis-ogenic peptides are being presented to these cells. In support of this hypothesis, CD8+ T cell clones cytolytic for HLA-B27 targets pulsed with Yersinia enterocolitica and Salmonella typhimurium have been isolated from ReA SF by one laboratory. However, proliferative responses to the triggering organism are greatly diminished in SFMC depleted of CD4+ T cells, and chlamydia specific cytotoxicity was not detected in SFMC from patients with chlamydia induced arthritis. Conversely, CD4+ T cells isolated from SF can readily be induced to proliferate in response to the triggering bacterium and several organism specific SF derived CD4+ T cell clones have been characterised.

In the animal model, CD4+ T cells have also been found to induce disease more rapidly and with more severe consequences than CD8+ T cells when the separate T cell subsets are transferred to nude HLA-B27 transgenic rats. Hence, other hypotheses have been proposed for the role of HLA-B27 in ReA, including the absence of a HLA-B27 restricted CD8+ T cell response, or presentation of a HLA-B27 derived peptide to CD4+ T cells.

One possible way of determining the relative importance of the CD4+ and CD8+ T cell subsets in the pathogenesis of ReA, is to examine the phenotype of these cells within the joint. Upon stimulation T cells upregulate expression of activation markers in a defined sequence. Expression of these markers on the T cells isolated from the SF of ReA patients could demonstrate which T cells are being stimulated, and therefore more likely to be involved in the inflammatory process. These activation markers include CD69, CD25, and HLA-DR. CD69 is a member of the C-type...
Table 1  ReA patients studied

<table>
<thead>
<tr>
<th>Patient</th>
<th>HLA-B27 status</th>
<th>Sex</th>
<th>Age</th>
<th>Triggering organism</th>
<th>Duration of arthritis (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>+</td>
<td>M</td>
<td>20</td>
<td>Enteric (Salmonella)</td>
<td>5</td>
</tr>
<tr>
<td>2</td>
<td>+</td>
<td>M</td>
<td>26</td>
<td>Enteric</td>
<td>&lt;1</td>
</tr>
<tr>
<td>3</td>
<td>+</td>
<td>M</td>
<td>35</td>
<td>Salmonella</td>
<td>&lt;1</td>
</tr>
<tr>
<td>4</td>
<td>-</td>
<td>M</td>
<td>48</td>
<td>Chlamydia</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>+</td>
<td>F</td>
<td>48</td>
<td>Shigella</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>+</td>
<td>M</td>
<td>18</td>
<td>Chlamydia</td>
<td>1</td>
</tr>
<tr>
<td>7</td>
<td>+</td>
<td>M</td>
<td>21</td>
<td>Salmonella</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>+</td>
<td>M</td>
<td>19</td>
<td>GU (Chlamydia)</td>
<td>3</td>
</tr>
<tr>
<td>9</td>
<td>-</td>
<td>M</td>
<td>52</td>
<td>Shigella</td>
<td>1</td>
</tr>
<tr>
<td>10</td>
<td>-</td>
<td>F</td>
<td>36</td>
<td>Enteric</td>
<td>&lt;1</td>
</tr>
<tr>
<td>11</td>
<td>ND</td>
<td>M</td>
<td>34</td>
<td>Enteric</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>-</td>
<td>F</td>
<td>34</td>
<td>Enteric</td>
<td>1</td>
</tr>
<tr>
<td>13</td>
<td>-</td>
<td>M</td>
<td>34</td>
<td>Enteric (Vesinias)</td>
<td>1</td>
</tr>
<tr>
<td>14</td>
<td>+</td>
<td>M</td>
<td>32</td>
<td>Enteric (Salmonella)</td>
<td>5</td>
</tr>
</tbody>
</table>

ND = not determined. If the triggering organism could not be defined absolutely, the type of infection (that is, enteric or GU (genitourinary)) is noted with the suspected bacteria shown in parentheses.

Table 2  Monoclonal antibodies and secondary reagents used

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Isotype</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3-BIO</td>
<td>IgG1</td>
<td>Dako</td>
</tr>
<tr>
<td>CD4-BIO</td>
<td>IgG1</td>
<td>Dako</td>
</tr>
<tr>
<td>CD4-FTTC</td>
<td>IgG1</td>
<td>Dako</td>
</tr>
<tr>
<td>CD4-PE</td>
<td>IgG1</td>
<td>Dako</td>
</tr>
<tr>
<td>CD8-PE</td>
<td>IgG1</td>
<td>Dako</td>
</tr>
<tr>
<td>CD25-FTTC</td>
<td>IgG1</td>
<td>Dako</td>
</tr>
<tr>
<td>CD69-FTTC</td>
<td>IgG1</td>
<td>Dako</td>
</tr>
<tr>
<td>HLA-DR-FTTC</td>
<td>IgG1</td>
<td>Dako</td>
</tr>
<tr>
<td>TCR½-FTTC</td>
<td>IgG1</td>
<td>Becton Dickinson</td>
</tr>
<tr>
<td>TCR½-FTTC</td>
<td>IgG1</td>
<td>Becton Dickinson</td>
</tr>
<tr>
<td>CD45RA-FTTC</td>
<td>IgG1</td>
<td>Serotec</td>
</tr>
<tr>
<td>CD45RO-FTTC</td>
<td>IgG2a</td>
<td>Serotec</td>
</tr>
</tbody>
</table>

Secondary reagents
- Streptavidin-RED670 — Life Technologies (Paisley, Scotland)
- IgG1-FTTC — Dako
- IgG1-PE — Dako
- IgG1-BIO — Dako
- IgG2a-FTTC — Dako

Flow cytometry
PBMC and SFMC samples were divided into appropriate number of samples containing at least 1 × 10⁵ cells and washed in PBS containing 0.1% bovine serum albumin (Sigma) and 0.01% sodium azide (Sigma). All samples were labelled with anti-CD3-BIO in conjunction with anti-CD4-PE or anti-CD8-PE and an additional antibody specific for the appropriate surface marker conjugated to FITC. Cells were incubated in 100 µl of the combinations of antibodies diluted in PBS for 30 minutes at 4°C. After washing off excess antibody, streptavidin-RED670 was added for 30 minutes at 4°C and then the cells washed again. Immunofluorescence was detected with a Beckton Dickinson FACSort flow cytometer. Samples were gated on forward and side scatter to exclude dead cells. As the detectable emission spectra of the fluorochromes overlap slightly, cells were separately labelled with a single antibody conjugated to each fluorochrome and the flow cytometer compensated to ensure that the fluorochrome was only detected by single detector. Data were analysed using WinMDI Version 2 (Trotter@scripps.edu). The analysis was limited to T cells by excluding any cells that did not express CD3. T cells were scored positive for each surface marker if fluorescence was above that detected using an isotype matched negative control antibody.
Figure 1. CD4:CD8 ratio of T cells from control and ReA PB, and from ReA SF. The CD4:CD8 ratio of CD3^+ T cells isolated from PB or SF, or both, of control subjects and ReA patients is shown. Each data point represents one person, and the mean (SD) for each cohort is shown.

STATISTICAL ANALYSIS
The statistical significance of the results was determined using the Wilcoxon signed rank test for paired samples, or the Mann-Whitney test for unpaired samples.

Results
T CELL SUBSETS
To investigate the possibility of selective recruitment of one of the subsets of T cells into the joint, the ratio of CD4^+ and CD8^+ cells within the CD3^+ T cell population of the PB and SF of ReA patients, and in PB from healthy controls was analysed (fig 1). The mean (SD) CD4:CD8 ratios of control PB, ReA PB, and ReA SF were 1.84 (0.72), 2.24 (1.07), and 1.99 (1.23), respectively. None of these differs significantly from each other, nor from the reported mean CD4:CD8 ratio of 468 healthy blood donors (2.13 (1.04)). Patient 13 had a very high SF CD4:CD8 ratio (5.2), but this was not reflected in the paired PB (CD4:CD8 = 2.1).

The number of CD3^+ T cells expressing the αβ TCR and γδ TCR in ReA PB and SF was analysed (fig 2). Although some ReA patients had a small increase in the number of TCRγδ^+ T cells in their SF compared with paired PB, this difference was not significant when the cohort was analysed as a whole. TCR expression by PB T cells from ReA patients was also compared with that from control PB and no significant difference was found.

CD45 EXPRESSION
Expression of the different isoforms of CD45 is thought to differ in memory and naive T cell subsets. Cells that have not previously encountered antigen express predominantly CD45RA, whereas after stimulation most T cells are CD45RO^+. A high proportion (67.7% (13.0%)) of the CD3^+ T cells in the PB of both controls and ReA patients were found to be CD45RA^+ (fig 3). However, fewer of the T cells isolated from the SF of ReA patients expressed this molecule. Instead, the majority of these T cells (73.6% (17.7%)) were found to express CD45RO, the low molecular weight form of the CD45 molecule, associated with activated and memory T cells. Patient 12 had very high percentages of CD45RA^+ T cells, and a lower proportion of CD45RO^+ T cells, in both PB and SF. However, there was still an increase in the number of CD45RO^+ T cells in the SF when compared with the PB. The differences in the number of CD45RA^+ and CD45RO^+ T cells in ReA PB compared with SF did not reach significance (p=0.0625 for both CD45RA and CD45RO). More patients need to be analysed to determine whether this trend would achieve statistical significance.

Analysis of the expression of CD45RA and CD45RO on the CD4^+ and CD8^+ subsets of T cells (fig 4) showed that more of the CD4^+ T cells expressed CD45RO. This difference was significant in ReA SF (p=0.03) and in the combined control and ReA PB samples (p=0.05). Conversely, more of the CD8^+ T cells were found to express CD45RA^+ (ReA SF p=0.03, combined PB p=0.004). A significant difference was not found if the results from control and ReA PB were analysed independently, possibly a reflection of the comparatively small number of samples studied.

ACTIVATION MARKERS
Expression of activation markers on T cells is indicative of recent stimulation and therefore may be evidence that these T cells are involved in the pathogenesis of the arthritis. ReA PB was found to contain more HLA-DR^+ T cells than control PB (p=0.05) (fig 5C), but there were no significant differences between control and ReA PB in the number of T cells expressing CD69 or CD25. ReA SF was found to contain more CD3^+ T cells expressing CD69, CD25, and HLA-DR, when compared with ReA PB (p<0.0001 for each activation marker) (fig 5). When this increased expression of activation markers was analysed in the CD4^+ and CD8^+ T cell subsets, a significantly higher percentage of both CD4^+ and CD8^+ T cells within ReA SF, compared with paired ReA PB, expressed CD69 (CD4, p<0.002; CD8, p=0.003) and HLA-DR (p=0.001 for both CD4^+ and CD8^+ T cell subsets) (fig 6A and 6C, respectively). CD25 expression was significantly increased.

Figure 2. TCR expression in control and ReA PB, and ReA SF. The percentage of CD3^+ T cells expressing the αβ TCR and the γδ TCR is shown. Each data point represents one individual, and the mean (SD) for each cohort is shown.
on CD4+ T cells within ReA SF, compared with paired ReA PB (p=0.01); however, there was not a significant difference in the number of CD8+CD25+ T cells (fig 6B).

In all populations tested (that is, control PB, and ReA PB and SF) a higher percentage of CD4+ T cells, compared with CD8+ T cells, were CD25+ (control PB, p=0.008; ReA PB, p=0.0001; ReA SF, p=0.0005) (fig 6B). Analysis of HLA-DR expression in ReA SF showed that in most patients more CD8+ T cells than CD4+ T cells expressed this molecule, although this difference was not statistically significant (p=0.064). No differences in HLA-DR expression by the CD4+ and CD8+ T cell subsets were evident in control or ReA PB (fig 6C). Also, there were no differences in the proportion of CD69+ T cells in the CD4+ and CD8+ subsets in control PB, ReA PB or ReA SF (fig 6A).

**Discussion**

The association of ReA with HLA-B27 has led to the proposal that CD8+ T cells restricted by this allele may be involved in the pathogenesis of ReA.
of the disease and hence might be expected to be present in increased proportions in the T cell population of the joint. However, the results presented here (fig 1) show there was no significant difference in the percentages of CD4+ and CD8+ T cells when ReA PB and SF were compared. Interestingly, there was also no correlation between the CD4:CD8 ratios of paired samples of PB and SF from ReA patients, demonstrating that the population of T cells that has migrated into the inflamed joint is not just a reflection of the circulating T cells, and that other factors must be affecting the numbers of a particular subset of T cells that are present at an inflammatory site, for example, selective migration, proliferation or death within the joint. When the percentages of TCR\(\gamma\delta\) and TCR\(\gamma\delta\) T cells were compared, no significant differences were found between ReA PB and ReA SF (fig 2). Hence, although TCR\(\gamma\delta\) T cells have been shown to proliferate in response to yersinia in vitro, if this is occurring in vivo it is not reflected by an accumulation of these cells in the joint.

An in vitro model of transendothelial migration has been established, in which cells can migrate through human umbilical vein endothelial cells (HUVECs) into collagen gels from where they can be extracted and their phenotype determined. In this assay, CD8+ and TCR\(\gamma\delta\) T cells showed increased migration compared with CD4+ T cells. If this is also the case for in vivo migration of T cells out of the circulation and into the joint, you would expect to find increased proportions of these cells in the SF. As no increase in the proportion of TCR\(\gamma\delta\) T cells or CD8+ T cells was seen, this may imply that CD4+ T cells are being preferentially recruited to the joint, or alternatively, that these cells are proliferating within the joint.

This study demonstrates increased numbers of CD45RO+ T cells in the SF of ReA patients compared with their PB (fig 3), which is in agreement with two other studies that investigated CD45 expression on CD4+ T cells isolated from ReA SF. Figure 4 shows that there were differences in CD45RA and CD45RO expression on CD4+ and CD8+ T cell subsets; more of the CD45RO+ T cells were in the CD4+ T cell population while a higher proportion of the CD8+ T cells still expressed CD45RA. This may indicate that it is mainly the CD4+ T cell population that has encountered antigen, either within the joint or before migrating there. However, expression of the CD45 isoforms, and the correlation of this with a memory phenotype has not been extensively studied for CD8+ T cells. Also, further experiments using the in vitro model of migration through HUVECs into collagen gels, have shown that the majority of T cells that migrate are CD45RO+, but some CD45RA+ cells within both CD4+ and CD8+ T cell subsets can also migrate. These results have been corroborated in an in vivo model of inflammation and transendothelial migration.

Cells that have migrated into skin blisters overlying PPD induced delayed type hypersensitivity responses that can be harvested and their phenotype and function assessed. In these experiments, most cells found in the blisters are CD45RO+; however the percentage of T cells positive for this putative memory marker does increase over time, as does the mean fluorescence intensity of CD45RO staining, suggesting further maturation of the memory phenotype of the T cells within the site of inflammation. Hence, the presence of mainly CD45RO+ T cells in the SF of ReA patients may be a result of the selective migration of T cells with a particular phenotype, but
Analysis of T cell subsets in ReA patients

...further priming of T cells within the joint cannot be discounted.

A significant number of T cells isolated from the SF of ReA patients expressed activation markers when compared with PB T cells (fig 5). When expression of activation markers was analysed in the CD4+ and CD8+ T cell subsets (fig 6), CD8+ T cells are found to express the early and late activation markers, CD69 and HLA-DR; however very few were CD25+. In contrast, CD4+ T cells were found to express IL2Ru. The presence of IL2Ru on the CD4+ T cell population may explain the ease by which these T cells are cloned in vitro, with addition of exogenous IL2, from the SF of ReA patients. However, expression of CD25 does not necessarily indicate the presence of a functional high affinity IL2 receptor, which also requires β and γ subunits.33

In a similar study conducted on T cells isolated from the SF of rheumatoid arthritis (RA) patients, CD3+ T cells were found to express the activation markers CD69, HLA-DR, and VLA-1, but not CD25.34 This pattern of expression of activation markers is comparable to that found on ReA SF derived CD8+ T cells. Interestingly, RA SF derived T cells were found to coexpress early and late activation markers (for example, CD69 and HLA-DR). T cells isolated from PPD induced skin blisters were also found to express early and late activation markers, even if the T cells were analysed only 24 hours after injection of the PPD. This pattern of expression does not occur on T cells polyclonally stimulated in vitro, and the authors suggested this unusual phenotype may be a result of migration through the endothelium. In the study presented here it is not known if dual expression of early and late activation markers occurs on T cells isolated from ReA SF as analysis was limited to three samples being collected.

Activated T cells expressing CD25 are not necessarily involved in actively inducing inflammation; instead several animal models of autoimmune diseases have implicated CD4+CD25+ T cells in maintaining tolerance and thereby playing a part in limiting disease.35 36 Thymectomy of B6A mice at day 3 results in spontaneous development of autoimmune diseases, which can be transferred to syngeneic naive mice by CD4+ T cells. Injection of a monoclonal antibody to delete CD25+ T cells did not reduce the incidence of the disease in these mice, suggesting the CD25+ T cells are not playing a part in causing autoimmune disease. However, treatment of mice thymectomised at day 7 (which would not normally develop disease), or normal mice, with anti-CD25 did induce development of autoimmune disease.35 These findings lead the authors to propose that there is a population of CD4+ T cells expressing IL2Ru, which are T suppressor cells that are maintaining immune tolerance. Similar conclusions were drawn from experiments conducted in nude BALB/c mice that develop several autoimmune diseases when reconstituted with T cells depleted of CD4+CD25+ cells.37 If CD4+CD25+ cells are co-transferred autoimmune diseases can be prevented. Hence, in this animal model, it is proposed that the CD4+CD25+ T cells are helping to maintain self tolerance.

ReA, although lasting several months, usually resolves spontaneously. CD4+CD25+ T cells are found in the SF of these patients. In contrast RA is a chronic disease and CD25+ T cells are not detectable within the SF. In RA it could be proposed that the lack of CD4+CD25+ T cells in the joint are preventing self tolerance mechanisms and thereby allowing immune responses against self antigens to occur. Conversely, in ReA, CD4+CD25+ T cells are detected in the SF and a role for these cells may be in limiting the disease.

In conclusion, the results presented here show that both CD4+ and CD8+ T cells are activated in ReA SF; however more CD4+ T cells express CD25, while more CD8+ T cells are HLA-DR+. The presence of activated cells in both T cell subsets may indicate that both CD4+ and CD8+ T cells play a part in the pathogenesis of joint inflammation in ReA. Whether they are involved in initiating the inflammation or contributing to the resolution of the disease is still unclear. Functional studies on the T cell subsets, such as analysing the...
cytokines produced by these two subsets, may further dissect their respective roles.

We thank Dr D Carruthers, Dr G Kitas, and the staff of Queen Elizabeth Medical Centre, Birmingham, and Addenbrooke’s Hospital, Cambridge, for providing SF and PB samples. This work was supported by the Arthritis and Rheumatism Council (UK) and the Medical Research Council (UK).


